- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03910244
Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HHT is associated with substantial morbidity, leading to a reduced quality of life, decreased rate of employment and a high incidence of depression. There currently exists no medical therapy recognized as consistently efficacious in HHT. Reports of the efficacy of thalidomide in HHT, as well as interim results of a pilot trial of pomalidomide in HHT provide evidence of efficacy with minimal toxicity. The favorable efficacy:toxicity ratio of pomalidomide suggest that it may benefit patients with HHT.
This study is designed as a Phase II placebo-controlled double-blind study of pomalidomide in HHT patients with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks.
Primary Objective: To determine efficacy of pomalidomide compared to placebo for the reduction in severity of epistaxis after 24 weeks of treatment.
Secondary Objectives: To determine the safety and tolerability of pomalidomide for the treatment of HHT; to determine if pomalidomide treatment improves quality of life in HHT; to determine whether a continued response to pomalidomide is evident 4 weeks after treatment discontinuation; to develop a biorepository for future studies to define biomarkers predictive of pomalidomide response and allow investigations into the biology of HHT and mechanisms of pomalidomide.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
California
-
San Diego, California, United States, 92121
- UCSD Hemophilia and Thrombosis Treatment Center
-
San Francisco, California, United States, 94143
- UCSF Outpatient Hematology Clinic
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachussets General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Health Clinical Research Unit
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27517
- University of North Carolina
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Perelman School of Medicine
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine, Texas Children's Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Healthcare
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wiconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A clinical diagnosis of HHT as defined by the Curacao criteria
- Age > 18 years
- Platelet count ≥ 100,000/µl
- WBC ≥ 2,500/µl
- INR ≤ 1.4 and normal ± 2 sec activated partial thromboplastin time (aPTT or PTT per local laboratory designation) by local laboratory criteria (except for patients on a stable dose of warfarin or direct oral anticoagulants)
- Epistaxis severity score ≥ 3 measured over the preceding three months, measured at the screening visit
- A requirement for anemia, as determined by local laboratory hemoglobin assessment and normal ranges, and/or parenteral infusion of at least 250 mg of iron or transfusion of 1 unit of blood over the 24 weeks preceding the screening visit
- Females of childbearing potential (FCBP) must adhere to the scheduled pregnancy testing (once very two weeks) as required in the POMALYST REMS program. FCBP must a negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy.
- Ability to understand and sign informed consent
- All study participants must agree to be registered into the FDA mandated POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program
Exclusion Criteria:
- Women currently breast feeding
- Renal insufficiency, serum creatinine > 2.0 mg/dl
- Hepatic insufficiency, bilirubin > 2.0 (or >4.0 in the setting of a prior clinical or genetic diagnosis of Gilbert's syndrome) or transaminases > 3.0x normal
- Prior treatment with thalidomide or other imid drugs within previous 6 months
- Prior treatment with bevacizumab (systemic or nasal) within previous 6 weeks*
- Prior treatment with pazopanib within previous 6 weeks*
- The use of octreotide or oral estrogens within the previous month*
- History of prior unprovoked thromboembolism confirmed by venous ultrasound or other imaging modalities
- Peripheral neuropathy, confirmed by neurologic consultation
- Known underlying hypoproliferative anemia (i.e. myelodysplasia, aplastic anemia)
- Currently enrolled in other interventional trials
- Known hypersensitivity to thalidomide or lenalidomide.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Known SMAD-4 mutation, unless there has been a colonoscopy with normal (negative) results, or in which the patient has had no more than 5 small (in the opinion of the gastroenterologist) colonic polyps completely removed within the preceding 18 months
Anything that in the investigator's opinion is likely to interfere with completion of the study
- * Use of these treatments is not permitted during study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pomalidomide
Oral Pomalidomide will be provided as a capsule at 4 mg/day dose.
There will be 6 treatment cycles of 28 days (4 weeks) each.
Total treatment phase duration will be 24 weeks.
|
Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles.
The dose may be reduced to 3 or 2 mg/day based on specific AE criteria.
Other Names:
|
Placebo Comparator: Placebo
A placebo matching the study drug will be provided as a capsule.
There will be 6 treatment cycles of 28 days (4 weeks) each.
Total treatment phase duration will be 24 weeks.
|
Matching placebo will be given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Epistaxis Severity Score
Time Frame: Baseline to 24 weeks
|
To determine efficacy of pomalidomide compared to placebo for the change in Epistaxis Severity Score in the placebo and pomalidomide-treated group. The responses to each of the questions are converted to give a normalized ESS score which could range from a minimum of '0' (Not at all severe) to '10' (Very severe) |
Baseline to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of Parenteral Iron Administration
Time Frame: Baseline to 24 weeks
|
Amount of parenteral iron administered (in mg) during the 24 week treatment period in the pomalidomide and placebo groups
|
Baseline to 24 weeks
|
Amount of Packed red blood cell Transfusions
Time Frame: Baseline to 24 weeks
|
Amount of packed red blood cell transfusions (in units) during the 24 week treatment period in the pomalidomide and placebo groups
|
Baseline to 24 weeks
|
Change in PROMIS Satisfaction with Social Roles and Activities
Time Frame: Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in PROMIS Satisfaction with Social Roles and Activities Short Form (V2.0) T-score from baseline (randomization visit) to weeks 12 and 24 (key timepoint), and the 4 week post-treatment follow-up visit in the pomalidomide and placebo groups. The response to each of the questions are summed to obtain a raw score which could range from 8 (least satisfaction) to 40 (most satisfaction). The raw-score is translated to give a T-score for each participant. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. |
Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in HHT-Specific QOL
Time Frame: Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in the HHT-specific QOL total score from baseline to weeks 12 and 24 (key timepoint), and the 4 week post-treatment follow-up visit in the pomalidomide and placebo groups. The total score for the HHT-Specific survey is obtained by summing the responses to each of the 4 questions and could range from 0 (no limitations) to 16 (severe limitations). |
Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in average weekly epistaxis duration
Time Frame: Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in average weekly epistaxis duration from the four week screening period prior to randomization to weeks 8-12 and to weeks 20-24 (key timepoint), and to the 4 weeks post-treatment in the pomalidomide and placebo groups
|
Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PROMIS Emotional Distress-Depression Short Form (V1.0)
Time Frame: Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in PROMIS® Emotional Distress-Depression Short Form (V1.0) T-score from baseline (randomization visit) to weeks 12 and 24 (key timepoint), and the 4 week post-treatment follow-up visit in the pomalidomide and placebo groups. The response to each of the questions are summed to obtain a raw score which could range from 8 (least depressed) to 40 (most depressed). The raw-score is translated to give a T-score for each participant. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. |
Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in PROMIS Fatigue Short Form (V1.0)
Time Frame: Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Change in PROMIS® Fatigue Short Form (V1.0) T-score from baseline (randomization visit) to weeks 12 and 24 (key timepoint), and the 4 week post-treatment follow-up visit in the pomalidomide and placebo groups. The response to each of the questions are summed to obtain a raw score which could range from 6 (least fatigue) to 30 (most fatigue). The raw-score is translated to give a T-score for each participant. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. |
Baseline to 24 weeks, Baseline to 12 weeks and Baseline to 28 weeks
|
Red Blood Cell Transfusion or Parenteral Iron Infusion
Time Frame: Baseline to 24 weeks
|
Proportion of patients requiring no red blood cell transfusion or parenteral iron infusion during the 24 week treatment period in the pomalidomide and placebo groups
|
Baseline to 24 weeks
|
Change in the Epistaxis Severity Score
Time Frame: Baseline to 4, 8, 12, 16, 20, 24 and 28 weeks
|
Change in the ESS from baseline to that recorded at each individual patient assessment, including the 4 week post-treatment follow-up visit. The responses to each of the questions are converted to give a normalized ESS score which could range from a minimum of '0' (Not at all severe) to '10' (Very severe). |
Baseline to 4, 8, 12, 16, 20, 24 and 28 weeks
|
Change in the Epistaxis Severity Score
Time Frame: Baseline to 24 weeks
|
Change in the ESS from baseline to the average of the week 16, 20 and 24 assessments. The responses to each of the questions are converted to give a normalized ESS score which could range from a minimum of '0' (Not at all severe) to '10' (Very severe). |
Baseline to 24 weeks
|
Endoscopic Interventions for management of bleeding
Time Frame: Baseline to 24 weeks
|
Proportion of patients requiring endoscopic interventions for management of bleeding during the 24 week treatment period in the pomalidomide and placebo groups
|
Baseline to 24 weeks
|
Incidence and Severity of Adverse Events
Time Frame: Baseline to 24 weeks
|
Incidence and severity of adverse events in the pomalidomide and placebo groups including but not limited to a) Venous thromboembolism; b) Arterial thromboembolism; c) Thrombocytopenia; d) Neutropenia; e) Peripheral neuropathy; f) Fatigue; g) Constipation/diarrhea; h) Rash; and i) Any other AEs or SAEs of at least moderate severity that are possibly related to pomalidomide
|
Baseline to 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Keith McCrae, MD, The Cleveland Clinic
Publications and helpful links
General Publications
- Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010 Apr;120(4):838-43. doi: 10.1002/lary.20818. Erratum In: Laryngoscope. 2021 Dec;131(12):2834.
- McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015 Jan 26;6:1. doi: 10.3389/fgene.2015.00001. eCollection 2015.
- Chaturvedi S, Clancy M, Schaefer N, Oluwole O, McCrae KR. Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey. Thromb Res. 2017 May;153:14-18. doi: 10.1016/j.thromres.2017.03.003. Epub 2017 Mar 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Congenital Abnormalities
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Cardiovascular Abnormalities
- Vascular Malformations
- Telangiectasis
- Telangiectasia, Hereditary Hemorrhagic
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Pomalidomide
Other Study ID Numbers
- 133646
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The DCC will prepare de-identified data files for sharing. A final data sharing plan will be developed with NHLBI and the study Steering Committee. The data can be provided in SAS data sets and export files and documentation will be in PDF format.
The first level of data sharing will be with trial investigators. In addition, the DCC will be responsible for sharing study data with outside researchers, if approved by NHLBI and the SC.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Telangiectasia, Hereditary Hemorrhagic
-
Vaderis Therapeutics AGRecruitingHereditary Hemorrhagic Telangiectasia (HHT)United States, Spain, France, Belgium, Netherlands, Italy
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of Pittsburgh; Duke University; Barrow... and other collaboratorsActive, not recruitingHereditary Hemorrhagic Telangiectasia (HHT)Canada
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia (HHT)United Kingdom
-
University Hospital, EssenCompletedHereditary Haemorrhagic Telangiectasia (HHT)Germany
-
University of PennsylvaniaCompletedHereditary Hemorrhagic Telangiectasia (HHT)United States
-
University Hospital, EssenCompleted
-
Centre Hospitalier Universitaire DijonCompletedHereditary Hemorrhagic TelangiectasiaFrance
-
Hospices Civils de LyonCompletedHHT | Hemorrhagic Hereditary TelangiectasiaFrance
-
Unity Health TorontoThe Hospital for Sick Children; Sunnybrook Health Sciences Centre; National Institute... and other collaboratorsCompletedHereditary Hemorrhagic TelangiectasiaCanada
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedHereditary Hemorrhagic TelangiectasiaItaly
Clinical Trials on Pomalidomide Oral Product
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
University Hospital, BordeauxCompleted
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
Brigham and Women's HospitalUnknownChronic Kidney Diseases | HyperkalemiaUnited States
-
Peking Union Medical College HospitalUnknown
-
Xenon Pharmaceuticals Inc.CompletedHealthy VolunteersUnited Kingdom
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
National Cheng Kung UniversityNational Cheng-Kung University Hospital; Ministry of Science and Technology...Recruiting
-
Institut de Recherche pour le DeveloppementCompleted